Search clinical trials for: Empagliflozin 25 MG

Total 11548 results

Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Section for Affective Disorders; Northern Stockholm...
Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...

Recruiting

Cancer Related Major Depression Treated With a Single Dose of Psilocybin (CAPSI)

MDD

Sweden
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
Center for Outcomes Research and Clinical Epidemiology...
Italian Society of Diabetology

Not yet recruiting

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial (GOLDEN-AGE)

Diabetes Mellitus, Type 2
University of Arkansas

Withdrawn

Determination of Cannabinoid and Cannabinoid Metabolite Levels in Healthy Volunteers

Healthy

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
University of California, San Francisco
Johns Hopkins University; Baylor College of Medicine; Children's Hospital of... and other collaborators

Not yet recruiting

Zinc Supplementation in Sickle Cell Disease (ZnSCD)

Sickle Cell Disease

United States
Spanish Society of Cardiology
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Active, not recruiting

Dapagliflozin After Transcatheter Aortic Valve Implantation (DapaTAVI)

Aortic Stenosis | Transcatether Aortic Valve Implantation

Spain
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
University Medical Centre Ljubljana

Unknown

The Effects of Empagliflozin on Arterial Wall Characteristics

Diabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic Agents

Slovenia
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany
The University of Hong Kong

Recruiting

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) (CATCH-EM)

Type 2 Diabetes | Microvascular Coronary Artery Disease

Hong Kong
Chulalongkorn University

Recruiting

Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV

Pediatric HIV Infection

Thailand
Intercept Pharmaceuticals

Completed

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

Healthy

United States
Medicines for Malaria Venture
AbbVie

Completed

Malaria: Relative Bioavailability and Food Effect of DSM265

Healthy Volunteers

United States
Instituto Nacional de Ciencias Medicas y Nutricion...
National Council of Science and Technology, Mexico; Universidad Nacional Autonoma...

Unknown

Spironolactone on Acute Kidney Injury in Critically Ill Patients

Acute Kidney Injury
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Active, not recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Nanjing First Hospital, Nanjing Medical University

Unknown

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust

Not yet recruiting

Therapy to Maintain Remission in Dilated Cardiomyopathy (TRED-HF2)

Heart Diseases | Heart Failure | Cardiomyopathies | Cardiomyopathy, Dilated
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
George Clinical Pty Ltd
University Medical Center Groningen; Ground Zero Pharmaceuticals

Unknown

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Diabetes Mellitus, Type 2 | Impaired Renal Function

Canada
Cartesian Therapeutics

Active, not recruiting

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Relapse Multiple Myeloma

United States, Turkey
Research Institute of Virology, Ministry of Health...

Completed

Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

COVID-19 Respiratory Infection

Uzbekistan
Ain Shams University
Drug Research Centre, Cairo, Egypt

Completed

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Diabetes Mellitus | Pharmacokinetics | Pharmacodynamics

Egypt
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
Novartis Pharmaceuticals

Completed

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

Alzheimer's Disease

Netherlands, United States, Belgium, Germany, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
Tel-Aviv Sourasky Medical Center

Unknown

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Diabetes Mellitus, Type 2 | Weight Loss | Frailty | Sarcopenia

Israel
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
Hongchang Guo

Recruiting

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, France, Israel, Mexico, South Africa
EMS

Recruiting

Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Aphthous Stomatitis

Brazil
Medical University of Lodz

Recruiting

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Chronic Kidney Disease stage3

Poland
Fontem Ventures BV

Completed

A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations

Healthy Volunteers

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Ukraine, United States, Czechia, Poland, Argentina, Mexico, South Africa, Chile, Bulgaria, Colombia, Russian Federation
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Heart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Tor Biering-Sørensen

Recruiting

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With CKD (DECODE-CKD)

Chronic Kidney Diseases

Denmark

Search clinical trials for: Empagliflozin 25 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations